Immunoproteasome Activation Enhances the Recognition of Tumour Cells and Boosts Anticancer Immune Responses

The correct functioning of the human immune system depends on its ability to recognise danger, such as tumour cells, viruses, and bacteria. Scientists are learning how immunoproteasome activation can overcome the mechanisms by which cancer cells escape immune responses. Immunoproteasomes are small high molecular weight protein-degrading machines that signpost abnormal proteins made by cancer cells, directing the immune system against them. Dr James Driscoll at University Hospitals Cleveland Medical Center is using novel proprietary small molecules to selectively boost the catalytic activity of immunoproteasomes, which increases the tumour killing (or cytotoxic) effect of a group of white cells called T-cells. These findings provide a strong rationale for developing personalised therapeutics that target immunoproteasomes, for cancer and other immune-mediated conditions.